Skip to main content
. 2016 Jan 15;18(1):79–87. doi: 10.1016/j.hpb.2015.07.006

Table 3.

Univariate survival statistics – positive node patients

III-A. Univariate survival – patient characteristics Median (months) 3 Yr (%) 5 Yr (%) p
Overall survival
 n = 160 15.4 16.6 4.6
Univariate demographics
AGE (10 years), HR (95% CI) 1.34 (1.19, 1.57) <0.0001
Gender 0.1641
 Male 17.5 16.2 3.0
 Female 11.7 16.9 6.1
Comorbidities 0.5284
 None 18.0 (13.5, 21.5) 14.5 3.9
 One or more 9.3 (3.3, 21.4) 10.0 10.0



III-B. Univariate tumor characteristics Median (months) 3 Yr (%) 5 Yr (%) p
Grade 0.9956
 1–2 14.2 16.7 6.8
 3–4 16.6 15.7 1.9
Surgical margin 0.3986
 Negative 18.3 18.8 4.7
 Micro or macro positive 10.4 13.3 4.4
 Involved – not specified 11.8 17.2 8.6
Regional nodes examined 0.7122
 0
 1–3 11.7 16.6 7.2
 ≥4 63.4 1.7 0.0
Lymph nodes positive 0.3613
 0
 1–3 15.0 18.1 5.8
 4–11 15.4 10.5 0.0
Tumor size 0.0488
 <5 cm 18.23 25.3 12.6
 ≥5 cm 15.0 13.4 2.2



III-C. Univariate – operative outcome Median (months) 3 Yr (%) 5 Yr (%) p
Length of stay (10 fold increase), HR (95% CI) 1.29 (0.5, 3.1) 0.5613
Readmission 30 days 0.5376
 None 17.7 15.2 5.3
 Readmission 15.5 0.0 0.0



III-D. Univariate adjuvant therapy Median (months) 3 Yr (%) 5 Yr (%) p
Systemic treatment 0.0033
 Chemotherapy only 19.1 23.2 2.9
 Chemotherapy and radiation 20.1 31.0 12.1
 None 9.3 10.2 3.4

Missing data reported in Table 1. Kaplan–Meier curves of categorical variables compared with log rank test of homogeneity or trend test for 3 or more ordered levels. Continuous variables tested with Cox proportion hazards regression. HR, hazard ratio.